RXRX Q3 2023 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-22.6% YoY

Gross Profit

-$775,000-7.7% margin

Operating Income

-$100M-985.4% margin

Net Income

-$93M-920.8% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

-8.3%

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$74M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$631M

Total Liabilities

$193M

Stockholders' Equity

$438M

Cash & Equivalents

$387M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$13M	-22.6%
Gross Profit	-$775,000	-$2M	+67.1%
Operating Income	-$100M	-$63M	-59.1%
Net Income	-$93M	-$60M	-53.9%

Revenue Segments

License and Service

$10M96%

Grant

$431,0004%